Coolman Marianne, de Groot Christianne J M, Steegers Eric A P, Geurts-Moespot Anneke, Thomas Chris M G, Steegers-Theunissen Régine P M, Sweep Fred C G J
Department of Obstetrics and Gynaecology, Division of Obstetrics and Prenatal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):22-8. doi: 10.1016/j.ejogrb.2006.02.004. Epub 2006 Apr 11.
Haemostasis is a complex balance of activating and inhibitory pathways resulting in coagulation and lysis. Normal pregnancy is associated with hypercoagulation that is even more profound in complicated pregnancies.
To study the role of the plasminogen-activator system in complicated pregnancy with regard to haemostasis, it is essential to have reference values of components of this system during uneventful pregnancy. In this study we investigated the concentrations of six different components of the plasminogen-activator system preconceptionally, during and after uncomplicated pregnancies.
Tissue-type and urokinase-type plasminogen activator (tPA and uPA), plasminogen inhibitor type-1 and -2 (PAI-1 and-2), and the complexes between tPA and PAI-1, and between uPA and PAI-1 (tPA-PAI-1, uPA-PAI-1) were measured by ELISAs in blood obtained preconceptionally, at 6, 10, 20, 32 weeks of gestation, and 6 weeks after delivery in uncomplicated pregnancies (n=41; all six parameters n=22).
tPA and uPA concentrations decreased in the first 10 weeks of pregnancy and subsequently increased in the third trimester. PAI-1 concentrations increased in the third trimester and PAI-2 concentrations increased throughout pregnancy (preconception versus 32 weeks of gestation; 38.73 versus 102.23ng/ml, and 0.024 versus 151.06ng/ml, respectively). tPA-PAI-1 and uPA-PAI-1 complex concentrations decreased in the first trimester, followed by an increase in the third trimester. The concentrations of all components returned to the preconception values 6 weeks after delivery.
This study provides longitudinal data on activating and inhibitory components of the plasminogen-activator system during pregnancy. Insight in the longitudinal changes in these concentrations may be of help in the understanding of the thrombotic tendency in pregnancy complications such as preeclampsia.
止血是激活和抑制途径的复杂平衡,最终导致凝血和纤溶。正常妊娠与高凝状态相关,在复杂妊娠中这种状态更为明显。
为了研究纤溶酶原激活物系统在复杂妊娠止血方面的作用,有必要了解该系统各成分在正常妊娠期间的参考值。在本研究中,我们调查了正常妊娠孕前、孕期及产后六种不同纤溶酶原激活物系统成分的浓度。
通过酶联免疫吸附测定法(ELISA)检测孕前、妊娠6周、10周、20周、32周及产后6周的血液中组织型纤溶酶原激活物(tPA)、尿激酶型纤溶酶原激活物(uPA)、纤溶酶原激活物抑制剂-1(PAI-1)、纤溶酶原激活物抑制剂-2(PAI-2)以及tPA与PAI-1、uPA与PAI-1的复合物(tPA-PAI-1、uPA-PAI-1)的浓度(正常妊娠41例;所有六项参数均检测的22例)。
tPA和uPA浓度在妊娠前10周下降,随后在孕晚期升高。PAI-1浓度在孕晚期升高,PAI-2浓度在整个孕期升高(孕前与妊娠32周相比;分别为38.73对102.23ng/ml,以及0.024对151.06ng/ml)。tPA-PAI-1和uPA-PAI-1复合物浓度在孕早期下降,随后在孕晚期升高。所有成分的浓度在产后6周恢复到孕前水平。
本研究提供了妊娠期间纤溶酶原激活物系统激活和抑制成分的纵向数据。了解这些浓度的纵向变化可能有助于理解子痫前期等妊娠并发症中的血栓形成倾向。